DGAP-News: PAION AG / Key word(s): Change of Personnel
DAVID BERNSTEIN, M.D. JOINS PAION AS MEDICAL ADVISOR & NON EXECUTIVE
DIRECTOR OF PAION INC
07.05.2015 / 14:00
---------------------------------------------------------------------
DAVID BERNSTEIN, M.D. JOINS PAION AS MEDICAL ADVISOR & NON EXECUTIVE
DIRECTOR OF PAION INC
- Dr. Bernstein will support PAION in its effort to bring Remimazolam to
the U.S. market
- Dr. Bernstein will also provide PAION with strategic insight and work
closely with PAION's advisory board of U.S. thought leaders
- PAION to be present at the DDW congress (May 17-19, 2015) in
Washington, U.S. at booth 1865
Aachen, 07 May 2015 - PAION AG, a Specialty Pharmaceutical Company (ISIN
DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) is pleased to
announce today that David Bernstein, M.D. has agreed to become PAION's
Medical Advisor. In this role, Dr. Bernstein will participate in building
the company's U.S. relationships with the academic community, regulators,
associations and industry. He will also play an active role in the growth
of the company's value proposition, with a special focus on the U.S.
Dr. Bernstein will also be heavily involved in steering PAION's efforts
with its recently established medical advisory board, which consists of
U.S. national thought leaders in the field of gastroenterology who are also
participating in our phase III program.
Dr Wolfgang Söhngen, M.D., Ph.D., chief executive officer of PAION AG,
said, "I'm thrilled to continue to work with Dr. Bernstein to bring
Remimazolam to a commercial success. David's contributions in helping us
put together our medical advisory board last year were significant. We hope
this will be a long and rewarding relationship with one of the most
respected physicians in the field of gastroenterology."
Greg Papaz, president and chief executive officer of PAION, Inc., added:
"It is a privilege to have a physician of David's prestige as a director of
PAION Inc. I am confident he will help us achieve our goals in the U.S."
Dr. Bernstein is currently chief of hepatology for both North Shore
University Hospital and Long Island Jewish Hospital, as well as the
director of the Center for Liver Diseases for the North Shore LIJ Health
System and a professor of medicine at the Hofstra North Shore LIJ School of
Medicine. Dr. Bernstein has authored over 100 publications, 10 book
chapters, and has been the principle investigator in more than 100 clinical
trials. His work has been published in such prestigious journals as the New
England Journal of Medicine and The Lancet.
Dr. Bernstein has held elective offices in many national and international
societies. He is the current president of the Bockus International Society
of Gastroenterology and a former president of the New York Gastrointestinal
Association. He served for six years as the American College of
Gastroenterology governor for Long Island and was a member of numerous
other medical committees. Currently, he is a fellow of the American
Association for the Study of Liver Diseases, the American College of
Gastroenterology and the American College of Physicians. He also serves as
a special consultant to the New York State Department of Health. He has
received numerous awards recognizing his contributions, in academia, as a
clinician, and in the field of public health.
"I am delighted to be involved with Remimazolam, a welcome alternative for
which gastroenterologists have waited many years. I look forward to the
challenges ahead and I am confident that we will see the potential of
Remimazolam fully realized in the United States," commented Dr. Bernstein.
PAION will be present at the Digestive Disease week (DDW 2015) between May
17-19, 2015 in Washington, U.S. and will be available for discussions at
booth 1865 in the exhibition hall.
About Remimazolam
Remimazolam is an innovative ultra-short-acting general
sedative/anesthetic. As a result of its short duration of action and good
controllability, it has a preferable efficacy and safety profile relative
to other currently marketed anesthesia compounds. Remimazolam's rapid
offset is a consequence of its metabolism by tissue esterase enzymes that
are widely distributed throughout the body. Remimazolam has potential in
three indications:
- Procedural sedation (Lead indication U.S.)
- General anesthesia (Lead indication EU, Japan)
- ICU sedation (Phase II Japan)
Remimazolam is available for licensing outside China, Russia (CIS) Turkey,
MENA Region, South Korea and Canada, where the compound is partnered with
Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm and Pendopharm.
About PAION
PAION AG is a publicly-listed Specialty Pharma Company headquartered in
Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The
company has a track record of developing hospital-based treatments for
which there is substantial unmet medical need. PAION's strategy is to
participate in the commercialization of Remimazolam and extend its business
with a focus on anesthesia/critical care products. Remimazolam is the
building block for its future marketing activities.
For more information please visit www.paion.com
PAION Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com
Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.
---------------------------------------------------------------------
07.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info@paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
354461 07.05.2015
DGAP-News: DAVID BERNSTEIN, M.D. JOINS PAION AS MEDICAL ADVISOR & NON EXECUTIVE DIRECTOR OF PAION INC
| Source: EQS Group AG